FUSN Overview
Upcoming Projects (FUSN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (FUSN)
-
A Third Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Mar 12, 2024 at 01:00 PM EDT -
A Second Look: Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Feb 02, 2024 at 09:00 AM EST -
A Second Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Feb 01, 2024 at 04:30 PM EST -
Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LLY, LNTH, FUSN
Executed On: Jan 26, 2024 at 08:00 AM EST -
Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Jan 24, 2024 at 12:30 PM EST -
Discussing the potential of 225Ac-PSMA I&T, a targeted alpha therapy being developed by Fusion Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Ticker: FUSN
Executed On: Apr 19, 2023 at 05:00 PM EDT
Upcoming & Overdue Catalysts (FUSN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (FUSN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
